Area of research
Immunology · Molecular Biology
Research interest
Research focused on Cancer research and Cancer immunotherapy, with related work in Immunotherapy, Immune system, Adjuvant. Notable publications include 'A Novel d ‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy', 'CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy', and 'Engineered Nanovaccine Targeting Clec9a + Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist'.
Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy
Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy
Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway
Identification of a novel GLUT1 inhibitor with in vitro and in vivo anti-tumor activity
Engineered Nanovaccine Targeting Clec9a<sup>+</sup> Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist
An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy
Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway
Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis
A Novel <scp>d</scp>‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy
Antitumor activity of novel chimeric peptides derived from cyclinD/CDK4 and the protein transduction domain 4
A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase‐2